Alpha Tau Medical Ltd.
DRTS Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2019โFY2025
Last close ยท Oct 23, 2026
$13.16
2.0%
Revenue
Total sales reported in the income statement.
โ
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$42.6M
Free cash flow
Cash from operations minus capital spending.
โ$32.8M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$1.1B
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
โ
On โ$0.53 EPS (TTM)
What Alpha Tau Medical Ltd. does
No business description yet.
- Legal name
- Alpha Tau Medical Ltd.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F ยท Mar 9, 2026
- Accession ยท CIK
- 0001213900-26-025174
0001871321
Revenue and margins
Alpha Tau Medical Ltd. had โ of revenue in fiscal 2025.
FY19
Revenue โ
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue โ
FY19
Gross โ
Operating โ
Net โ
FCF โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY19
Net income โ$8.4M
FY20
Net income โ$8.9M
FY21
Net income โ$27.3M
FY22
Net income โ$33.8M
FY23
Net income โ$29.2M
FY24
Net income โ$31.8M
FY25
Net income โ$42.6M
FY19
Diluted EPS โ$0.25
FY20
Diluted EPS โ$0.22
FY21
Diluted EPS โ$0.67
FY22
Diluted EPS โ$0.53
FY23
Diluted EPS โ$0.42
FY24
Diluted EPS โ$0.45
FY25
Diluted EPS โ$0.53
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY19
Return on capital โ
Return on equity โ
Return on assets โ
FY20
Return on capital โ
Return on equity โ
Return on assets โ16.8%
FY21
Return on capital โ
Return on equity โ
Return on assets โ57.3%
FY22
Return on capital โ
Return on equity โ95.3%
Return on assets โ41.6%
FY23
Return on capital โ
Return on equity โ30.7%
Return on assets โ25.6%
FY24
Return on capital โ
Return on equity โ43.2%
Return on assets โ32.8%
FY25
Return on capital โ
Return on equity โ61.0%
Return on assets โ44.4%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ$32.8M in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY19
Free cash flow โ$8.2M
FY20
Free cash flow โ$11.0M
FY21
Free cash flow โ$14.7M
FY22
Free cash flow โ$24.8M
FY23
Free cash flow โ$24.4M
FY24
Free cash flow โ$22.0M
FY25
Free cash flow โ$32.8M
FY19
Cash from operations โ$6.9M
Capital spending $1.3M
FY20
Cash from operations โ$7.3M
Capital spending $3.8M
FY21
Cash from operations โ$11.8M
Capital spending $2.9M
FY22
Cash from operations โ$23.9M
Capital spending $0.9M
FY23
Cash from operations โ$18.0M
Capital spending $6.4M
FY24
Cash from operations โ$19.8M
Capital spending $2.2M
FY25
Cash from operations โ$26.7M
Capital spending $6.1M
Cash from operations
Capital spending
Dividends, buybacks and share count
Alpha Tau Medical Ltd. returned โ to shareholders in fiscal 2025. The diluted share count rose 15.2%.
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY19
Diluted shares 0.03B
FY20
Diluted shares 0.04B
FY21
Diluted shares 0.04B
FY22
Diluted shares 0.06B
FY23
Diluted shares 0.07B
FY24
Diluted shares 0.07B
FY25
Diluted shares 0.08B
Balance sheet
Cash, debt and the ratios that show how comfortably Alpha Tau Medical Ltd. can carry it.
FY19
Cash $1.8M
Debt โ
FY20
Cash $15.6M
Debt โ
FY21
Cash $31.3M
Debt โ
FY22
Cash $105M
Debt โ
FY23
Cash $81.8M
Debt โ
FY24
Cash $59.6M
Debt โ
FY25
Cash $73.1M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $31.3M | $105M | $81.8M | $59.6M | $73.1M |
| Interest coverage | โ | โ | โ475.7x | โ119.0x | โ121.9x |
| Current ratio | 7.4x | 24.5x | 12.1x | 7.4x | 7.5x |
| Quick ratio | 7.4x | 24.5x | 12.1x | 7.4x | 7.5x |
| Total assets | $42.2M | $120M | $107M | $86.2M | $106M |
| Total liabilities | $23.0M | $14.5M | $22.9M | $23.5M | $28.6M |
| Shareholders' equity | โ$34.8M | $106M | $84.5M | $62.7M | $77.1M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 4 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 6 |
| Accruals ratio | โ | โ3.1% | โ32.5% | โ12.2% | โ9.8% | โ12.4% | โ16.6% |
| Altman Z'' | โ | 1.68 | โ3.47 | 9.08 | 2.93 | โ1.37 | โ1.51 |
7 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | $6.6M | $7.5M | $11.4M | $20.9M | $26.4M | $27.0M | $32.1M |
| Operating income | $8.0M | โ$9.2M | โ$13.8M | โ$32.1M | โ$35.7M | โ$36.0M | โ$42.3M |
| Interest expense | โ | โ | โ | โ | $0.1M | $0.3M | $0.3M |
| Pretax income | $8.3M | โ$8.7M | โ$27.3M | โ$33.7M | โ$29.1M | โ$31.7M | โ$42.5M |
| Income tax | โ$0.1M | $0.2M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M |
| Net income | โ$8.4M | โ$8.9M | โ$27.3M | โ$33.8M | โ$29.2M | โ$31.8M | โ$42.6M |
| Diluted EPS | โ$0.25 | โ$0.22 | โ$0.67 | โ$0.53 | โ$0.42 | โ$0.45 | โ$0.53 |
| Diluted shares | 0.03B | 0.04B | 0.04B | 0.06B | 0.07B | 0.07B | 0.08B |
| Cash flow | |||||||
| Cash from operations | โ$6.9M | โ$7.3M | โ$11.8M | โ$23.9M | โ$18.0M | โ$19.8M | โ$26.7M |
| Capital expenditure | $1.3M | $3.8M | $2.9M | $0.9M | $6.4M | $2.2M | $6.1M |
| Free cash flow | โ$8.2M | โ$11.0M | โ$14.7M | โ$24.8M | โ$24.4M | โ$22.0M | โ$32.8M |
| Depreciation and amortization | $0.1M | $0.1M | $0.8M | $1.0M | $1.1M | $1.1M | $1.2M |
| Stock-based compensation | $0.5M | $0.6M | $0.8M | $6.7M | $7.9M | $9.9M | $10.6M |
| Balance sheet | |||||||
| Cash and short-term investments | $1.8M | $15.6M | $31.3M | $105M | $81.8M | $59.6M | $73.1M |
| Current assets | โ | $47.5M | $32.6M | $106M | $85.8M | $64.2M | $78.3M |
| Current liabilities | โ | $2.1M | $4.4M | $4.3M | $7.1M | $8.7M | $10.5M |
| Property and equipment, net | โ | $5.4M | $7.5M | $7.5M | $12.8M | $13.9M | $19.7M |
| Total assets | โ | $53.0M | $42.2M | $120M | $107M | $86.2M | $106M |
| Total liabilities | โ | $7.5M | $23.0M | $14.5M | $22.9M | $23.5M | $28.6M |
| Shareholders' equity | โ$0.2M | โ$8.4M | โ$34.8M | $106M | $84.5M | $62.7M | $77.1M |
| Returns | |||||||
| Return on capital employed | โ | โ18.2% | โ36.5% | โ27.7% | โ35.6% | โ46.5% | โ44.4% |
| Return on equity | โ | โ | โ | โ95.3% | โ30.7% | โ43.2% | โ61.0% |
| Return on assets | โ | โ16.8% | โ57.3% | โ41.6% | โ25.6% | โ32.8% | โ44.4% |
| Return on tangible equity | โ | โ | โ | โ32.0% | โ34.5% | โ50.7% | โ55.3% |
| Growth | |||||||
| Share count change | โ | 19.1% | 0.6% | 56.7% | 9.2% | 0.8% | 15.2% |
| Financial health | |||||||
| Interest coverage | โ | โ | โ | โ | โ475.7x | โ119.0x | โ121.9x |
| Current ratio | โ | 22.7x | 7.4x | 24.5x | 12.1x | 7.4x | 7.5x |
| Quick ratio | โ | 22.7x | 7.4x | 24.5x | 12.1x | 7.4x | 7.5x |
| Quality scores | |||||||
| Altman Z'' | โ | 1.7 | โ3.5 | 9.1 | 2.9 | โ1.4 | โ1.5 |
| Accruals ratio | โ | โ3.1% | โ32.5% | โ12.2% | โ9.8% | โ12.4% | โ16.6% |
Source: SEC EDGAR XBRL filings (CIK 0001871321). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.